A Phase II Study of PNT2258 in Patients with Richter's Transformation
Research type
Research Study
Full title
A Phase II Study of PNT2258 in Patients with Richter's Transformation
IRAS ID
187514
Contact name
Valerie Ratheau
Contact email
Sponsor organisation
ProNai Therapeutics Inc
Eudract number
2015-001814-85
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
PNT2258 is a unique drug designed to target genes within cancer cells to induce cell death. This study will test PNT2258 in patients with Richter's Transformation to determine what effect it has on their tumours and survival rate.
Twenty patients will be recruited initially, with 49 patients enrolled in total if the trial continues after the first stage. Patients will be treated with infusions of the drug for as many cycles as they can tolerate or until their disease progresses.
The study will be sponsored by ProNAi therapeutics.REC name
South Central - Oxford B Research Ethics Committee
REC reference
16/SC/0010
Date of REC Opinion
10 Mar 2016
REC opinion
Further Information Favourable Opinion